Solfredoc RTU^®

TPGS-Docetaxel Solution for Infusion 20 mg, 80 mg & 120 mg

Sayre Therapeutics offers a Docetaxel formulation with the efficacy of conventional Docetaxel minus the side effects associated with the solvent.

• • Indication: An anti-neoplastic agent approved for the treatment of Breast cancer, Prostate cancer, Gastric cancer and Head & Neck cancer.
  • Formulation:  Solvent free Docetaxel formulated using TPGS (Vitamin-E) as an excipient
  • Ready-to-use solution: Obviates the preparation of the drug before infusion
  • Minimal/no hypersensitivity reactions: In a clinical trial, Solfredoc^® was shown to be associated minimal/nil hypersensitivity reactions.
  • TPGS serves as an efficient drug carrier: across the blood brain-barrier with high drug encapsulation efficiency, cell uptake, cytotoxicity and desired bio-distribution of the formulated drug.

* Incidence of Hypersensitivity reactions only